临床医学论著

PRPS2、CDK6和Rb在子宫颈癌演变中的表达及机制探讨*

  • 陈少华 ,
  • 张燕 ,
  • 李明 ,
  • 慈红非 ,
  • 蔡兆根 ,
  • 李楠
展开
  • 蚌埠医学院第一附属医院病理科,蚌埠医学院病理学教研室,安徽蚌埠 233030
李 楠

收稿日期: 2023-12-09

  网络出版日期: 2025-05-14

基金资助

蚌埠医学院科技重点项目(2020byzd038);2021年度省级大学生创新创业计划(S202110367063)

Expression and mechanism of PRPS2, CDK6 and Rb in the evolution of cervical cancer

  • CHEN Shaohua ,
  • ZHANG Yan ,
  • LI Ming ,
  • CI Hongfei ,
  • CAI Zhaogen ,
  • LI Nan
Expand
  • Department of Pathology, the First Affiliated Hospital of Bengbu Medical College, Bengbu Medical College, Bengbu 233030, China

Received date: 2023-12-09

  Online published: 2025-05-14

摘要

目的:探讨磷酸核糖焦磷酸合成酶2(phosphoribosyl pyrophosphate synthetases 2, PRPS2)、细胞周期蛋白依赖性激酶6(cyclin dependent kinase 6, CDK6)、视网膜母细胞瘤(retinoblastoma, Rb)蛋白在各级别宫颈上皮内病变及宫颈癌组织中的表达情况及与人乳头瘤病毒(human papilloma virus,HPV)感染的相关性,明确各因子与宫颈癌发生演变的关系及其可能的调控机制,为宫颈癌的诊疗提供更丰富的手段及依据。方法:选取2018年1月至2018年12月蚌埠医学院第一附属医院临床病理科宫颈癌病例40例、宫颈高级别上皮内病变40例、宫颈低级别上皮内病变30例,以子宫颈慢性炎20例作为对照组,免疫组化检测PRPS2、CDK6、Rb在各级别宫颈病变中的表达情况。收集各病例HPV感染信息,分析各组HPV感染情况及与各因子相关性。结果:PRPS2、CDK6、Rb在对照组子宫颈慢性炎、低级别子宫颈上皮内病变、高级别子宫颈上皮内病变及宫颈癌中阳性率表达差异有统计学意义(χ2=44.02,P<0.05;χ2=31.81,P<0.05;χ2=36.08,P<0.05)。组间PRPS2、CDK6、Rb表达部分差异有统计学意义。相关性分析显示PRPS2、CDK6、Rb蛋白表达三者之间具有相关性。各组HPV感染率存在差异,且各因子表达与HPV感染有一定关联。结论:子宫颈癌的逐级演进与PRPS2、CDK6蛋白过表达呈正相关关系,与Rb蛋白表达缺失存在一定相关性,可能协同HPV通过CDK6-Rb-E2F通路推动细胞周期的转化促进肿瘤的形成。

本文引用格式

陈少华 , 张燕 , 李明 , 慈红非 , 蔡兆根 , 李楠 . PRPS2、CDK6和Rb在子宫颈癌演变中的表达及机制探讨*[J]. 包头医学院学报, 2025 , 41(4) : 45 -49 . DOI: 10.16833/j.cnki.jbmc.2025.04.009

Abstract

Objective:To investigate expressions of phosphoribosyl pyrophosphate synthetase 2(PRPS2), cyclin dependent kinase 6(CDK6), retinoblastoma(Rb) in different stages of cervical intraepithelial lesions and cervical cancer and their correlation with human papilloma virus(HPV) infection, aiming to determine the relationship of different factors with the evolution of cervical cancer and their possible regulatory mechanism. Methods: A total of 130 patients in the Department of Pathology, the First Affiliated Hospital of Bengbu Medical College from January 2018 to December 2018 were selected, including 40 cases of cervical cancer(cervical cancer group), 40 cases of high-grade squamous intraepithelial lesion(HSIL) of cervix(HSIL group), 30 cases of low-grade squamous intraepithelial lesion(LSIL) of cervix(LSIL group) and 20 cases of chronic inflammation(the control group). The expression of PRPS2, CDK6 and Rb in different grades of cervical lesions were detected using immunohistochemistry. HPV infection data of each case was collected, and the HPV infection condition and the correlation of each factor were analyzed. Results: The positive rates of PRPS2, CDK6, and Rb in the control group, LSIL group, HSIL group and cervical cancer group were (10.0%, 40.0%, 77.5%, 87.5%), (10.0%, 36.7%, 50.0%, 82.5%), and (80.0%, 63.3%, 32.5%, 10.0%) respectively, (χ2=44.02, P<0.05; χ2=31.81, P<0.05; χ2=36.08, P<0.05). There were significant differences in the expression levels of PRPS2, CDK6 and Rb between groups. The correlation analysis result indicated that protein expressions of PRPS2, CDK6 and Rb were correlated. There were differences in the HPV infection rate between groups. The expression of each factor was associated with HPV infection. Conclusion: The gradual evolution of cervical cancer was positively correlated with the overexpression of PRPS2 and CDK proteins, and related to the loss of Rb protein expression, which may accelerate transformation of cell cycle by cooperating with HPV through the CDK6-Rb-E2F pathway to promote tumor formation.

参考文献

[1] Liu S, Wang HY, Mu J, et al.MiRNA-211 triggers an autophagy-dependent apoptosis in cervical cancer cells: regulation of Bcl-2[J]. Naunyn Schmiedebergs Arch Pharmacol, 2020, 393(3): 359-370.
[2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA A Cancer J Clin, 2018, 68(6): 394-424.
[3] Cunningham JT, Moreno MV, Lodi A, et al. Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer[J]. Cell, 2014, 157(5): 1088-1103.
[4] Luo YL, Yuan JQ, Huang J. Correction: role of PRPS2 as a prognostic and therapeutic target in osteosarcoma[J]. J Clin Pathol, 2021, 74(8): e12.
[5] Li Q, Wang SG, Wu ZY, et al. DDX11-AS1 exacerbates bladder cancer progression by enhancing CDK6 expression via suppressing miR-499b-5p[J]. Biomed Pharmacother, 2020, 127: 110164.
[6] He ZY, Dang J, Song AL, et al. NEAT1 promotes colon cancer progression through sponging miR-495-3p and activating CDK6 in vitro and in vivo[J]. J Cell Physiol, 2019, 234(11): 19582-19591.
[7] Dall′acqua A, Sonego M, Pellizzari I, et al. CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation[J]. EMBO Mol Med, 2017, 9(10): 1415-1433.
[8] Tong XM, Zhao FP, Thompson CB. The molecular determinants of de novo nucleotide biosynthesis in cancer cells[J]. Curr Opin Genet Dev, 2009, 19(1): 32-37.
[9] Liu GH, Luo Y, Hou PF. PRPS2 enhances resistance to cisplatin via facilitating exosomes-mediated macrophage M2 polarization in non-small cell lung cancer[J]. Immunol Invest, 2022, 51(5): 1423-1436.
[10] Miao WL, Wang YS. Targeted quantitative kinome analysis identifies PRPS2 as a promoter for colorectal cancer metastasis[J]. J Proteome Res, 2019, 18(5): 2279-2286.
[11] Lv YJ, Wang XS, Li XY, et al. Nucleotide de novo synthesis increases breast cancer stemness and metastasis via cGMP-PKG-MAPK signaling pathway[J]. PLoS Biol, 2020, 18(11): e3000872.
[12] 熊宇迪, 李天琪, 余笑言, 等. 细胞周期蛋白激酶4和6抑制剂在肿瘤治疗中研究进展[J]. 中华肿瘤防治杂志, 2020, 27(22): 1859-1864.
[13] Chen J, Guerriero E, Lathrop K, et al. Rho/ROCK signaling in regulation of corneal epithelial cell cycle progression[J]. Invest Ophthalmol Vis Sci, 2008, 49(1): 175-183.
[14] Kannan K, Sharpless NE, Xu J, et al. Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model[J]. Proc Natl Acad Sci USA, 2003, 100(3): 1221-1225.
[15] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[16] Ren CC, Zhu YH, Yang L, et al. Diagnostic performance of HPV E6/E7 mRNA assay for detection of cervical high-grade intraepithelial neoplasia and cancer among women with ASCUS Papanicolaou smears[J]. Arch Gynecol Obstet, 2018, 297(2): 425-432.
[17] Hoppe-Seyler K, Bossler F, Braun JA, et al. The HPV E6/E7 oncogenes: key factors for viral carcinogenesis and therapeutic targets[J]. Trends Microbiol, 2018, 26(2): 158-168.
文章导航

/